Screener
Veracyte VCYT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Income tax provision | 1,267 | 381 |
| Net income | $28,707 | $7,047 |
| Earnings per share: | ||
| Basic | $0.36 | $0.09 |
| Diluted | $0.35 | $0.09 |
| Shares used to compute earnings per common share: | ||
| Basic | 79,536,601 | 78,028,254 |
| Diluted | 81,313,588 | 80,056,024 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's EPS (diluted)?
- Veracyte (VCYT) reported EPS (diluted) of $0.35 in Q1 2026.
- How has Veracyte's EPS (diluted) changed year-over-year?
- Veracyte's EPS (diluted) increased by 288.9% year-over-year, from $0.09 to $0.35.
- What is the long-term trend for Veracyte's EPS (diluted)?
- Over 4 years (2021 to 2025), Veracyte's EPS (diluted) has grown at a -7.7% compound annual growth rate (CAGR), from -$1.13 to $0.82.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Veracyte's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude